- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Waist to Height Ratio.
Displaying page 1 of 1.
EudraCT Number: 2012-003426-24 | Sponsor Protocol Number: CTU079G | Start Date*: 2013-02-13 |
Sponsor Name:Riemser Pharma GmbH | ||
Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b... | ||
Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m² | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016921-32 | Sponsor Protocol Number: HSJD-OB-TRP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ... | |||||||||||||
Medical condition: obesity | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001189-13 | Sponsor Protocol Number: C4181005 | Start Date*: 2021-02-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA | |||||||||||||
Medical condition: Achondroplasia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) DK (Prematurely Ended) BE (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001080-24 | Sponsor Protocol Number: NL76906.068.21 | Start Date*: 2021-04-08 |
Sponsor Name:Maastricht University | ||
Full Title: The effect of plant stanol ester consumption on the vaccination response to a COVID-19 vaccine | ||
Medical condition: COVID-19 vaccination respons of people with BMI 27-35 kg/m2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-001502-28 | Sponsor Protocol Number: PRED-AID | Start Date*: 2019-02-11 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study) | |||||||||||||
Medical condition: Adrenal insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001746-40 | Sponsor Protocol Number: PRO-ARX201-701 | Start Date*: 2008-08-25 | |||||||||||
Sponsor Name:Ambrx, Inc., USA | |||||||||||||
Full Title: A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone D... | |||||||||||||
Medical condition: Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001313-14 | Sponsor Protocol Number: 2007-189-2 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Dutch growth research foundation | |||||||||||||
Full Title: Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS. | |||||||||||||
Medical condition: Prader Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002491-40 | Sponsor Protocol Number: CLMB763X2202 | Start Date*: 2019-04-03 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized patient-and-physician blinded, placebo-controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathy | |||||||||||||
Medical condition: Diabetic Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003937-17 | Sponsor Protocol Number: NN2211-1860 | Start Date*: 2008-04-28 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: The effect of liraglutide compared to sitagliptin, both in combination with metformin in subjects with type 2 diabetes. A 26-week, randomised, open-label, active comparator, three-armed, parallel-... | |||||||||||||
Medical condition: type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) NL (Completed) GB (Completed) ES (Completed) FR (Completed) IT (Completed) SK (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001670-34 | Sponsor Protocol Number: AZP01-CLI-002 | Start Date*: 2015-01-26 | |||||||||||||||||||||
Sponsor Name:Alize Pharma | |||||||||||||||||||||||
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in... | |||||||||||||||||||||||
Medical condition: Prader-Willi Syndrome | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005109-23 | Sponsor Protocol Number: AWC LowE | Start Date*: 2009-08-05 | |||||||||||||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||||||||||||
Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound. | |||||||||||||||||||||||
Medical condition: Age/menopause related changes in the artery wall composition after menopause | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006766-21 | Sponsor Protocol Number: MINI-SPIOMET | Start Date*: 2022-09-02 | |||||||||||
Sponsor Name:Hospital de Girona Dr. Josep Trueta | |||||||||||||
Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study. | |||||||||||||
Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003119-22 | Sponsor Protocol Number: EYP001-202 | Start Date*: 2019-05-20 | |||||||||||
Sponsor Name:ENYO Pharma SA | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis | |||||||||||||
Medical condition: Nonalcoholic steatohepatitis with likely stage F2 to F3 fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001547-12 | Sponsor Protocol Number: DC2017RACELINES01 | Start Date*: 2017-12-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) NO (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.